Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer

• Published in: Molecular cancer Vol. 17; no. 1; pp. 67 - 6
• Main Authors: Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Tomiguchi, Mai, Sueta, Aiko, Murakami, Keiichi, Iwase, Hirotaka
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.02.2018; BioMed Central; BMC
• Subjects: AKT1 mutation; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Care and treatment; Cell-free DNA; Cell-Free Nucleic Acids; Class I Phosphatidylinositol 3-Kinases - genetics; Development and progression; DNA, Neoplasm; ESR1 mutations; Estrogen Receptor alpha - genetics; Estrogen receptor-positive breast cancer; Female; Hormone therapy; Humans; Kaplan-Meier Estimate; Letter to the Editor; Mutation; PIK3CA mutations; Prognosis; Proto-Oncogene Proteins c-akt - genetics; ESR1 mutations; Cell-free DNA; Estrogen receptor-positive breast cancer; PIK3CA mutations; AKT1 mutation

The somatic activation of PI3K/AKT pathway mutations, PIK3CA and AKT1, and ESR1 mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive procedure to quickly assess and monitor disease progression or therapeutic effect in breast cancer (BC) patients, but the clinical significance...